Institutional Investor (August 5)
Series A and B is the “inflection point…. where institutional capital typically expects clarity; clinical data, market readiness, and a signal that someone else has de-risked the science. But in women’s health, those signals often do not arrive. Not because the companies aren’t progressing but because the validation layers that used to feed the pipeline e.g. public grants, translational studies, pilot programs have eroded.” Because validation doesn’t arrive, “promising science stalls, not because of bad data, but because no one wants to be first.”
Tags: Clarity, Clinical data, De-risked, Inflection point, Institutional capital, Market readiness, Pilot programs, Promising, Public grants, Science, Series A and B, Signals, Stalls, Validation, Women’s health
Washington Post (July 24)
Somehow Trump’s appeal keeps rising. “His support within the Republican Party has risen and solidified. It now stands at around 90 percent, which is what tin-pot dictators get in rigged elections.” This leaves many befuddled, but his trick is telling people what they already believe. Playing to prejudice is Trump’s appeal. “He validates the thinking—some of it ugly—of many Americans. To them, Helsinki doesn’t matter and even Putin doesn’t matter. Only Trump does. To them, he hates the right people.”
Tags: Appeal, Dictators, Hate, Helsinki, Prejudice, Putin, Republican, Solidified, Trump, Validation
